Company: INTS
Filing Date: 2025-04-24
Form Type: S-1/A
Source: 0001628280-25-019491
Chunk: 2

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: S-1/A
Chunk 2
---
 REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY JURISDICTION WHERE THE OFFER OR SALE IS NOT PERMITTED.

#### Up to 2,307,692 Shares of Common Stock
<div align='center'>Up to 2,307,692 Series B-1 Common Warrants to Purchase Up to 2,307,692 Shares of Common Stock

Up to 2,307,692 Series B-2 Common Warrants to Purchase Up to 2,307,692 Shares of Common Stock

Up to 2,307,692 Pre-Funded Warrants to Purchase Up to 2,307,692 Shares of Common Stock

Up to 2,307,692 Shares of Common Stock Underlying the Pre-Funded Warrants

Up to 4,615,384 Shares of Common Stock Underlying the Series B-1 Common Warrants and Series B-2 Common Warrants</div>

We are offering on a reasonable best efforts basis up to 2,307,692 shares of our common stock, par value $0.0001 (the “Common Stock”), together with warrants to purchase up to 4,615,384 shares of our Common Stock. Each share of Common Stock, or a pre-funded warrant in lieu thereof, is being sold together with a common warrant to purchase one share of Common Stock (the “Series B-1 Common Warrant”) and an additional common warrant to purchase one share of Common Stock (the “Series B-2 Common Warrant”, and together with the Series B-1 Common Warrant, the “Common Warrants”). The shares of Common Stock and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. The assumed public offering price for each share of Common Stock and the accompanying Common Warrants is $1.30, which was the closing price of our Common Stock on The Nasdaq Capital Market (“Nasdaq”) on April 23, 2025.

Each Common Warrant will have an assumed exercise price per share of $1.30 (equal to the assumed combined public offering price per share of Common Stock and accompanying Common Warrants) and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise